Background Currently, many laboratories have switched the traditional screening algorithm (TSA) to reverse screening
Introduction
Treponema pallidum subspecies pallidum (T. pallidum), the spirochete causes syphilis and has been regarded as a stealth pathogen because of its poorly antigenic and non-inflammatory surface. 1 Syphilis is therefore a challenging sexually transmitted infection (STI) for humans. Currently, the resurgence of infectious syphilis is the main reason syphilis remains a public health concern worldwide. [2] [3] [4] [5] The World Health Organization (WHO)
Global Health Sector Strategy aims to reduce syphilis and gonorrhoea incidence over 2018-2030 by 90%, and to reduce the incidence of congenital syphilis to <50 cases per 100 000 live births by 2030. 6 China had 448 620 officially reported syphilis cases in 2012, almost doubling the number of cases reported in 2007; additionally, the rate of primary and secondary syphilis in 2012 was 13 .44 cases per 100 000 population, increasing by 1.5 times since 2007. 7 China's syphilitic epidemic resurged with the commencement of economic prosperity in the 1980s, [8] [9] [10] especially in the areas of prosperous south-eastern seaboard. Shanghai, for instance, had the highest rate of total syphilis cases from 2000 to 2006 in China, and the trophy was transferred to Zhejiang Province from 2007. 11, 12 Given the severe per capita syphilis burden, China's Ministry of Health promulgated a 10-year plan for the Prevention and Control of Syphilis (2010-2020) in 2010, 12 established interim targets regarding the epidemic of the 'great pox'. Diagnosis of syphilis is based on clinical manifestations and laboratory serology for the detection of two distinct types of antibodies including nontreponemal (anti-lipoid) and treponemal antibodies. These serological tests are employed in two different algorithms: the traditional screening algorithm (TSA) primarily performed with a nontreponemal test (NTT) such as TRUST or rapid plasma reagin (RPR); if the result was reactive, then confirmed with a specific treponemal test (TT) such as T. pallidum particle agglutination assay (TPPA). The reverse screening algorithm (RSA) initiated with a TT and reflexed to a NTT for assessment of the infection activity and the response to treatment.
In recent years, more and more high-volume laboratories have implemented treponemal immunoassays [e.g., enzyme immunoassays (EIAs), chemiluminescence immunoassays (CIAs) as the first screening test], driven by the increasing demand for syphilis screening (e.g., pre-operation, pre-transfusion and maternal prenatal care) and the high throughputs of automated EIAs/CIAs.
Currently, several critical publications have raised concerns regarding syphilis screening algorithms. In 2010, the Centers for Disease Control and Prevention of the United States (US CDC) recommended that the screen-reactive sera with nonreactive NTT results should be confirmed with a second TT when the RSA is implemented, 13 in accordance with two studies published in 2008 and 2011. 14, 15 Although these landmark findings are ref-
erences for the implementation of the RSA, the inherent limitation of the studies from the US CDC was the lack of parallel nontreponemal screening of all samples. Therefore, it was unclear which algorithm yielded a higher false-reactive rate.
Since the implementation of CIA in the Immunology Division of Shanghai Sixth People's Hospital, we have witnessed the confusion arising from this contemporary treponemal test. Hence, we attempt to explore issues in syphilis screening through the direct comparison of the two screening algorithms in a large population with a low prevalence of syphilis.
Materials and methods

Subjects
A total of 110 663 serum samples were submitted for syphilis screening to the Immunology Division of Shanghai Jiaotong University Affiliated Sixth People's Hospital (SH6PH), excluding the sera from patients younger than 18 years old and duplicated sera from the same patients. All the patients were from various departments except for the department of STD, and the obstetrics as well during the study period, from January 2009 to July 2012.
Screening algorithms
The RSA, started with a chemiluminescence immunoassay (CIA), which called the Chemclin TP assay (Beijing Chemclin Biotech Co., Ltd., Beijing, China), was employed for syphilis screening, and the TSA was initiated with TRUST (Rongsheng Biotech Co., Ltd., Shanghai, China). All sera submitted for syphilis testing were screened with dual algorithms in parallel throughout the study period (approximately 140 tests, were assigned into two batches each day, 6 days a week, totalling 42 700/year).
Treponema pallidum particle agglutination assay The TPPA (Fujirebio Diagnostics Inc., Tokyo, Japan) test, which is based on the agglutination of coloured gelatin particle carriers sensitized with T. pallidum (Nichols Strain) antigen, was routinely used to detect treponemal antibody prior to the use of the Chemclin TP assay in the present laboratory.
Chemclin TP First, all sera were obtained after centrifuging [2500 g (relative centrifugal force, RCF) for 10 min] and were tested with the Chemclin TP assay on an automatic platform (Personal Lab; Adaltis Inc., Rome, Italy). The Chemclin TP assay is a microplate-based CIA. The microplate is coated with the recombinant antigens of T. pallidum (TpN15, 17, 47), which can react with treponemal antibodies in the sera. The combination of antigen and antibody continues binding to the enzyme-antigen conjugate during incubation. Then the luminescent signals (transformed into relative luminescence units, RLUs) induced by the further reaction with luminal and peroxide can be read by another instrument (chemiluminescence reader Chemclin 3.1 plus, Beijing Chemclin Biotech Co., Ltd.) after 5 min. All screened sera were determined as reactive with an index value (the ratio of sample RLU/cut-off, S/CO value) ≥1 and nonreactive with an index value <1. The test results of the aforementioned CIA (90 sera) could be given in 90 min.
Toluidine red unheated serum test Second, after the first batch of 90 sera were all pipetted and downloaded, they were screened in parallel according to the TSA by TRUST, a manual immunoassay based on the macroscopic flocculation reaction on the standard cards. All the results could be received in about 60 min without the interference of the on-board CIA results. A quantitative test would determine the final titres of the TRUSTreactive sera. Furthermore, each reactive sample was reflexively tested using TPPA. Finally, the reactive results screened with CIA were confirmed with TPPA and reflexively tested with TRUST to avoid interference from the results of the TSA. The testing profile mentioned above could proceed in relatively separate channels, and the tests could validate each other (e.g., CIA-reactive serology vs EuroWB VITROS TPA-reactive sera were further tested with a treponemal Western blot assay (Euroimmun IgG Western Blot, EuroWB; Euroimmun AG, L€ ubeck, Germany) on Euro-Blot-Master platform(EBM44; Euroimmun AG). If the coloured bands were revealed on the strips, it suggested that the sera contained anti-T. pallidum antibodies. Strips with coloured bands were compared against the positive control strip with bands identifying the TpN15, TpN17, TpN45 and TpN47 antigens supplied in the kit. The EuroWB results were divided into nonreactive (no bands for the specific antigens), borderline (one distinctive band for a specific antigen) and reactive (more than one distinctive band for the specific antigens) results.
All screening tests were performed according to the instructions of the manufacturers.
Statistical analysis
Student's t-test was used to compare the mean, and the Mann-Whitney test was used to compare the distributions of non-Gaussian distributed variables (e.g., CIA index values) from two unmatched groups. A P value of <0.05 was considered to be statistically significant. All analyses were conducted using GraphPad Prism 5.0 (GraphPad Software, Inc, San Diego, CA, USA).
Results
Overall, 110 663 serum samples were tested with both screening algorithms in the current study. Among the sera screened, samples from 934 (0.8%) patients were reactive by the TSA (TRUST), while 2259 (2.0%) were reactive by the RSA (CIA) (Fig. 1) . Both algorithms showed a low prevalence of syphilis in our study.
Traditional screening algorithm
Among the 934 TRUST-reactive results, 67 (7.2%) were nonreactive treponemal results by CIA and TPPA, suggesting that the initial results of TRUST were biological false-positive (BFP) results; 840 (89.9%) were reactive by CIA and TPPA; 27 (2.9%) were CIA-reactive but TPPA-nonreactive (Fig. 1) .
Reverse screening algorithm
Of the 2259 CIA-reactive serology results, 1392 (61.6%) patients had TRUST-nonreactive results. Of these discordant serology results, 350 (25.1%) were TPPA-nonreactive and 1042 (74.9%) were TPPA-reactive (Fig. 1) . A total of 182 sera from the 350 TPPA-nonreactive sera were further tested by VITROS TPA, of which 155 (85.2%) were nonreactive and 27 (14.8%) were reactive. The 27 VITROS TPA-reactive sera were further tested with EuroWB, of which 11 (41%) were indeterminate, 6 (22%) were nonreactive and 10 (37%) were reactive (Table 1) . Among the 10 EuroWB-reactive sera, two seroconverted to TPPA 1:80+/À after 1-year follow-up (Fig. 2) . Moreover, of the total 867 (37.9%) patients with TRUST-reactive results among the 2259 CIA-reactive patients (concordant serology results), 27 (3.1%) were unexpectedly TPPA-nonreactive and 840 (96.9%) were TPPA-reactive (Fig. 1) . In addition, CIA index values were compared for CIA-reactive/TRUST-nonreactive and CIA-reactive/TRUST-reactive patients according to TPPA status. The distribution of the index Screening for syphilis with dual algorithms values (S/CO) and the demographic characteristics from CIAreactive patients are described in Tables 2 and 3 , respectively.
Discussion
In China, the TSA has been routinely conducted in medical settings for decades except in resource-limited areas. However, the disadvantages of the NTT have resulted in some flaws during the clinical practice, mainly due to its relatively low sensitivity and specificity compared with the TT. The cause for this low sensitivity is the slightly longer duration of the anti-lipoid antibody generation and likely nonreactive serology in some situations (e.g., individuals with late/latent syphilis, early primary syphilis or treated syphilis). 15 Meanwhile, the BFP phenomenon due to various non-syphilitic conditions (e.g., viral hepatitis, infectious mononucleosis, systemic lupus erythematosus, leprosy and malignancy) can decrease the specificity of NTT. 16 Therefore, some laboratories in Shanghai implemented the dual diagnostic assays in parallel to avoid the disadvantages of the TSA which could lead to medical disputes due to the low reactive serology in primary syphilis; as a result, more laboratories prefer to offer both serological results (e.g., nontreponemal and treponemal tests) to minimize this occasional occurrence, even if the possibility of missing the detection of syphilis is rare in general hospitals serving low-prevalence populations who are hospitalized for diseases other than STIs. The reason for implementing dual diagnostic assays may be due to self-protection; terrible violence against Chinese doctors is frequently reported in China. 17, 18 Given the increased implementation of the RSA instead of the TSA, more attention has been focused on this paradigm shift. Clearly, our study showed that the RSA yielded an increased false-reactive rate [377/2259 (16.7%) vs. 67/934 (7.2%), P < 0.0001], although it also identified more screen-reactive sera compared with the TSA [2259 (2.0%) vs. 934 (0.8%), P < 0.0001]. Meanwhile, a high percentage of sera had discordant serology results (CIA-reactive, TRUST-nonreactive) that could not be detected by the TSA, perhaps were due to multiple conditions (e.g., previously successfully treated syphilis, late/latent syphilis, early syphilis or no syphilis). 19 It suggests that patients with late/latent syphilis who have not had their syphilis infections previously managed could be identified by the RSA and could be treated to prevent further complications. The RSA could also identify patients with early syphilis prior to the presence of nontreponemal antibodies, who could be subsequently treated as soon as possible. Hence, two standpoints coexist regarding the use of the RSA for syphilis screening: one opinion states that the RSA is probably not suitable for all clinical laboratories and medical settings because it may lead to increased patient follow-up and over-treatment due to the higher proportion of screen-reactive results. 15, 20, 21 The second opinion states that the RSA has the potential ability to identify early primary and late/latent syphilis. 22, 23 Of the CIA-reactive/TRUST-nonreactive sera, the median index value of the TPPA-reactive subgroup was significantly higher at 15.2 compared with the TPPA-nonreactive subgroup at 2.2 (P < 0.0001; Table 2 ). Additionally, the TPPA-reactive subgroup had a higher proportion of index values ≥5 (90.5% vs. 24.3%), suggesting a high probability of false-reactive results exists among patients with low index values from CIA screening. As a result, we established an internal protocol for routine syphilis screening, in which discordant sera with low CIA index values should be confirmed by TPPA and/or retested with CIA or another TT; these recommendations were in absolutely agreement with those endorsed by the US CDC 15 and the Association of Public Health Laboratories (APHL). 24 Therefore, a third TT could be helpful and is said to have great expectation as a 'tiebreaker', 25 but it's not in fact. The results of further testing of the 182 CIA-reactive/TRUST-nonreactive/TPPA-nonreactive sera can be seen in Fig. 2 . The final interpretations of the eight WB-reactive sera (excluding two seroconverted sera) were determined to be syphilis unlikely after further clinical evaluation of identifying signs, symptoms or history of syphilitic infections. If recent exposure is suspected for anyone mentioned above, redraw the sample in 2-4 weeks and repeat the RSA. 26 On the contrary, the results with low index values will be considered false reactive. Notably, 27 (3.1%) sera were TPPA-nonreactive among the CIA-reactive/TRUST-reactive sera; according to recommendations from the US CDC, these patients are not recommended for further confirmation by TPPA, 15 although there is no significance in the distribution of index values between the subgroups (P = 0.9437, Table 2 .). However, the mean age of the patients from the TRUST-reactive/TPPA-nonreactive subgroup is older than patients reactive to both assays [76 (95% CI, 71-81 years old) vs. 56 (95% CI, 55-57 years old), P < 0.0001, Table 3 ]. Furthermore, there are a high proportion of patients with advanced age in this subgroup. Given the fact that 88.9% individuals (24/27) of this subgroup are ≥60 years old (P < 0.0001, Table 3 ), we speculate that the advanced age is the likely cause of the conflicting results. The definite reason, for either the false reactivity of CIA or the low sensitivity of TPPA, is not clear. Of the 27 individuals, no one has the positive physical examination of the signs and symptoms. All of them denied the past history of syphilis infection and recent exposure. More information by further follow-ups may be helpful to reveal the final status of the patients.
The limitations of our current study include the following: first, the study was only aimed at a population with a low prevalence of syphilis; the samples were mainly from the patients being treated for multiple medical issues, but the STD and obstetrics patients were excluded. Therefore, the influence of these excluded populations is not clear in our study. Second, older patients without clinical manifestations often lack relevant clinical history and majority of them would deny the history of STIs including syphilis, for traditional Chinese morality often induces severe social discrimination. Hence, the true history of the TRUST-reactive/TPPA-nonreactive subgroup in our study is undetermined. The reactive CIA screening results confused the interpretation of the diagnosis given by TPPA results and clinical history in our laboratory; more researches (such as follow-ups of the inconclusive subgroups by repeating the algorithms at regular intervals; adoption of the Western blot technique) are needed to unravel how to diagnose syphilis given the complicated ties among different tests and clinical histories.
Conclusions
In conclusion, our study found several crucial findings in a large hospital-based population. Despite the limitations, the present study revealed that the TSA is more suitable for laboratories with low-volume samples due to the lower false-reactive rate and its cost-effectiveness. In contrast, for high-volume laboratories, the RSA definitely fulfils the increasing demanding for syphilis screening through the high throughput from the automated instruments; meanwhile, a dilemma that should be confronted is the confusion caused by the likely false-reactive results detected by CIA. More steps (e.g., re-testing the serum by TPPA, complete physical examination, detailed clinical history and medical follow-up) should be taken with such patients. Further testing results with TPPA, VITROS TPA and EuroWB suggested the false-reactive CIA screening results and the likely false-nonreactive TPPA results when the reactive treponemal results screened with RSA were to be identified. Currently, each diagnostic assay for syphilis screening has limitations that make the diagnosis of syphilis a challenging endeavour; therefore, the integration of laboratory results and clinical findings is important for the diagnosis and management of adult syphilis.
